新聞Haystackoncology partnered with TriSalus Life Sciences, Inc. on Dec 26th '23.Baltimore-based Haystack Oncology, a Quest Diagnostics company and developer of personalized MRD technology, has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.
新聞Haystackoncology partnered with The Cancer Institute of New Jersey on Nov 18th '23.Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology's industry-leading personalized MRD technology (Haystack MRD(TM) to help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast cancer (TNBC) patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.
新聞Haystackoncology expands offices to United Kingdom, Northern Europe, Europe.Haystack Oncology plans to relocate its workforce to the 135,000 square foot building at 101 W. Dickman Street and part of the mixed-use Baltimore Peninsula, in late 2023.
